Major Weight Loss With Tirzepatide; Top Endo Hospitals; Renaming Obesity?

In two late-stage trials of tirzepatide, adults with obesity or overweight lost about 26% of their body weight after an initial intensive lifestyle intervention, said Eli Lilly.

Compared with DPP-4 inhibitors or sulfonylureas, both SGLT2 inhibitors and GLP-1 receptor agonists were linked with a reduced risk of major adverse cardiovascular events. (The Lancet Diabetes & Endocrinology)

The Mayo Clinic in Rochester, Minnesota nabbed the top spot on the U.S. News & World Report‘s list of top hospitals for diabetes and endocrinology in 2023-2024. The second and third spots went to NYU Langone Hospitals and New York-Presbyterian Hospital-Columbia and Cornell, both in New York City.

A factory where semaglutide (Wegovy) pens are made reportedly breached sterile-safety rules several times over the years. (Reuters)

A 20-week exercise program involving aerobic and resistance training improved body composition, cardiorespiratory fitness, and cardiometabolic risk factors in kids with overweight or obesity — but had no effect on mental health. (JAMA Network Open)

Should obesity be renamed “adiposity-based chronic disease?” (Obesity Reviews)

Some patients taking semaglutide (Wegovy, Ozempic) for weight loss and diabetes reported experiencing severe gastroparesis. (CNN)

Actress Naomi Watts detailed “spiraling out of control” after experiencing menopause symptoms at age 36. (People)

How long should patients with obesity be on drug treatment? (The BMJ)

Please enable JavaScript to view the

comments powered by Disqus.